To test whether avasimibe could overcome imatinib resistance in CML, K562R cells displaying BCR-ABL mutation-independent resistance were treated with avasimibe and imatinib. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.